Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo
08:00am, Monday, 17'th Mar 2025
New Analyses Related to Aficamten Expand on its Metabolism Pathways, Treatment Effect Associated with Combination Therapy with Disopyramide and Longer-Term Effect on Cardiac Structure and Function SOU
Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten
10:22am, Sunday, 16'th Mar 2025
Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. If all goes well, it could be approved by September 2025. Aficamten had favorable Phase 3 data, so it could have solid
Cytokinetics to Participate in March Investor Conferences
04:00pm, Monday, 03'rd Mar 2025
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor confere
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus
02:16pm, Friday, 28'th Feb 2025
CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate aficamten upon a potential FDA approval.
Cytokinetics, Incorporated (CYTK) Q4 2024 Earnings Call Transcript
07:49pm, Thursday, 27'th Feb 2025
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Diane Weiser - Senior Vice President, Corporate Affairs Robert Blum - Presi
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
06:15pm, Thursday, 27'th Feb 2025
Cytokinetics (CYTK) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.38 per share a year ago.
Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update
04:00pm, Thursday, 27'th Feb 2025
Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and China
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:05am, Thursday, 20'th Feb 2025
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Wednesday, 19'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 14, 2025 it granted stock options to purchase an aggregate of
Cytokinetics to Announce Fourth Quarter Results on February 27, 2025
04:00pm, Thursday, 13'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2025 at 4
Cytokinetics Names Robert E. Landry to Board of Directors
07:30am, Tuesday, 11'th Feb 2025
Appointment Deepens Financial and Operational Expertise of Board as Company Approaches Potential Commercialization
Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:00pm, Wednesday, 05'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to par
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Tuesday, 04'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it granted stock options to purchase an aggregate of 6
Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm
12:22pm, Thursday, 30'th Jan 2025
NEW YORK , Jan. 30, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Cytokinetics, Inc. (NASDAQ: CYTK) breached their
Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program
07:30am, Thursday, 30'th Jan 2025
Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach
